PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis c |
| Symptom | |chronic infection |
| Sentences | 129 |
| PubMedID- 23327540 | chronic infection with hepatitis c virus (hcv) is common, but underdiagnosed and undertreated worldwide. |
| PubMedID- 24609763 | chronic infection with hepatitis c virus (hcv) often affects the b-cell compartment, leading to the occurrence of autoimmunity and b-cell lymphoproliferation, in particular mixed cryoglobulinemia and b-cell lymphomas. |
| PubMedID- 24211330 | End stage liver disease caused by chronic infection with the hepatitis c virus (hcv) is a leading indication for liver transplantation, yet outcomes are poor since the liver graft is rapidly re-infected by hcv. |
| PubMedID- 23575038 | chronic infection with hepatitis c virus (hcv) affects >170 million individuals, approximately 3% of the world population, and is responsible for approximately 350,000 deaths every year 1. |
| PubMedID- 23118525 | chronic infection with the hepatitis c virus (hcv) is a major cause of liver-related invalidity and mortality worldwide. |
| PubMedID- 19657792 | Objective: to evaluate liver function and hemostatic parameters in postmenopausal women who have chronic infection with the hepatitis c virus and climacteric symptoms and are undergoing hormone therapy (ht) (standard dose of transdermal continuous combined hormone therapy). |
| PubMedID- 22187946 | chronic infection with hepatitis c virus (hcv), mainly genotype 1, has been shown to be associated with insulin resistance and type 2 diabetes. |
| PubMedID- 22039483 | For example, chronic infection with hepatitis c virus (hcv) results from reduction of the dimerization of mitochondrial antiviral signaling protein (mavs) by hcv nonstructural (ns) protein ns3/4a protease to levels that are too low to mount strong enough antiviral immune responses . |
| PubMedID- 21187906 | chronic infection with the hepatitis c virus (hcv) is amongst the most frequent causes of liver cirrhosis and hepatocellular carcinoma 1. |
| PubMedID- 25820703 | Background: chronic infection with hepatitis c virus (hcv) genotype 2 or 3 can be treated with sofosbuvir without interferon. |
| PubMedID- 21477324 | chronic infection with hepatitis c virus (hcv) is a major and growing public health problem, which could easily lead to chronic liver disease, cirrhosis and even hepatocellular carcinoma 1. |
| PubMedID- 22792259 | chronic infection with hepatitis c virus (hcv) is considered a major risk for chronic liver failure. |
| PubMedID- 22537438 | Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis c virus (hcv) have become the standard of care. |
| PubMedID- 23617810 | chronic infection with hepatitis c virus (hcv) affects 130–200 million people worldwide 1. |
| PubMedID- 25604355 | Although chronic infection with hepatitis c virus (hcv) is the leading indication for liver transplantation in the united states, graft and patient survival rates are reduced because of hcv recurrence after transplant. |
| PubMedID- 23207339 | Objective: to investigate the in vivo functional roles of the la autoantigen (la), the human homologue of the 33-kda vesicle-associated membrane protein-associated protein (hvap-33), and the subunit gamma of the human eukaryotic initiation factors 2b (eif2bgamma) as co-infection factors supporting chronic infection with hepatitis c virus (hcv). |
| PubMedID- 20108989 | chronic infection with hepatitis c virus (hcv) is a major healthcare problem, affecting an estimated 170 million people worldwide. |
| PubMedID- 24533893 | In 2009, several independent studies revealed a strong association between genetic variation in the interleukin-28b (il28b) locus and the outcome of treatment for chronic infection with hepatitis c virus (hcv). |
| PubMedID- 23315914 | chronic infection with the hepatitis c virus (hcv) is a leading cause of global morbidity and mortality. |
| PubMedID- 24114816 | Background and rationale: chronic infection with the hepatitis c virus (hcv) is associated with a higher prevalence of insulin resistance compared to the general population. |
| PubMedID- 23151512 | chronic infection with hepatitis c virus (hcv) is an important cause of end stage liver disease worldwide. |
| PubMedID- 21994707 | chronic infection with hepatitis c virus (hcv) frequently leads to liver cirrhosis or liver cancer. |
| PubMedID- 25314116 | Historically, clinical trials of regimens to treat chronic infection with hepatitis c virus (hcv) have used, as their primary efficacy endpoint, a sustained virological response (svr)-defined as hcv rna levels below a designated threshold of quantification-24 weeks after the end of treatment (svr24). |
| PubMedID- 21870716 | chronic infection with hepatitis c virus is nowadays responsible for many cases of liver disease. |
| PubMedID- 23936821 | chronic infection with hepatitis c virus (hcv) affects almost 200 million people worldwide, representing a leading cause of cirrhosis and anticipated liver-related death 1. |
| PubMedID- 25476473 | During the interview reported treatment of chronic infection with hepatitis c virus (hcv) with peginterferon and ribavirin. |
| PubMedID- 26209383 | We report on the first well-tolerated and successful use of sofosbuvir-based therapy in a patient in whom chronic infection with hepatitis c had preceded the development of b-cell non-hodgkin's lymphoma. |
| PubMedID- 23872239 | chronic infection with hepatitis c virus (hcv) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. |
| PubMedID- 24719731 | Background: chronic infection with hepatitis c virus (hcv) is increasingly recognized as a major global health problem. |
| PubMedID- 24695489 | The egyptian population has a heavy burden of liver disease, mostly due to chronic infection with hepatitis c virus . |
| PubMedID- 26225247 | chronic infection with hepatitis c virus (hcv) affects about 170 million people worldwide and is a major cause of liver complications. |
| PubMedID- 21183794 | chronic infection with hepatitis c virus (hcv) is a major public health problem, with nearly 170 million infected individuals worldwide. |
| PubMedID- 24717818 | An estimated 3.2 million persons in the united states have chronic infection with hepatitis c virus (hcv). |
| PubMedID- 23672452 | The present study analyzed the data of men who participated in the kncss between 2006 and 2008. among the 2,441 men included initially, we excluded 152 subjects who, by self-report, had existing health problems related to hepatitis infection, (i.e., liver cirrhosis), were hbsag-positive, and/or had chronic infection associated with hepatitis c. we further excluded 52 men due to the presence of hepatitis b surface antibodies (anti-hbs) prior to vaccination as well as 63 others due to missing information pertaining to major variables. |
| PubMedID- 25408375 | chronic infection with hepatitis c virus (hcv) is caused by an inadequate immune response. |
| PubMedID- 22947522 | chronic infection with hepatitis c virus (hcv) is a major and growing public health concern worldwide, including in latin america. |
| PubMedID- 20642483 | Sex and age differences in lipid response to chronic infection with the hepatitis c virus in the united states national health and nutrition examination surveys. |
| PubMedID- 25893197 | chronic infection with hepatitis c virus negatively regulates both the innate and adaptive arms of the immune system. |
| PubMedID- 21760886 | chronic infection with hepatitis c virus (hcv) is an important cause of liver cancer and end-stage liver disease in the united states and worldwide . |
| PubMedID- 22878466 | Mental health problems frequently occur in chronic infection with the hepatitis c virus (hcv) and during antiviral treatment with pegylated interferon-alpha (pegifnalpha) and ribavirin. |
| PubMedID- 24685721 | Background & aims: production of interferon (ifn)-gamma by natural killer (nk) cells is attenuated during chronic infection with hepatitis c virus (hcv). |
| PubMedID- 23071503 | chronic infection with hepatitis c virus (chcv) is present in 3% of the world’s population with prevalence ranging from 0.1–5% in different european countries 1. |
| PubMedID- 26034765 | Overall, liver-related death, mainly due to chronic infection with hepatitis c virus (hcv) or hepatitis b virus, represents the most frequent cause of non-aids-related death 2. |
| PubMedID- 26157746 | Hepatocellular carcinoma (hcc) is a growing clinical problem, being the second leading cause of cancer deaths worldwide (globocan, http://globocan.iarc.fr) and one of the only increasing causes of cancer-related mortality in the u.s.1 in contrast to developing countries in the asia-pacific regions and sub-saharan africa, where hepatitis b virus (hbv) is the major risk factor for hcc, chronic infection with hepatitis c virus (hcv) has been a leading cause of hcc in developed countries2 and is the first indication for liver transplantation for patients with hcc in the u.s.3 worldwide, the world health organization (who) estimates that 3% of the world's population has been infected with hcv and that more than 170 million people are currently chronic carriers of hcv (who, www.who.int). |
| PubMedID- 20974315 | Background: the standard treatments for chronic infection with the hepatitis c virus (hcv) are peginterferon alpha-2a or alpha-2b plus ribavirin, but it remains unclear if one has a better efficacy and safety profile. |
| PubMedID- 26262613 | chronic infection with hepatitis c virus (hcv) can result in severe liver diseases, including cirrhosis and hepatocellular carcinoma 1. |
| PubMedID- 24475147 | hepatitis c virus (hcv) leads to chronic infection in the majority of infected individuals due to lack, failure, or inefficiency of generated adaptive immune responses. |
| PubMedID- 24822024 | chronic infection with hepatitis c virus (hcv) affects more than 170 million people worldwide and is a leading cause of anticipated liver-related death due to the development of cirrhosis and its complications.1 in the last 10 years, standard of care anti-hcv treatment has been founded on the combination of peginterferon (peg-ifn) plus ribavirin (rbv), whose main disadvantages were suboptimal rates of sustained virological response (svr) in difficult-to-treat patients (hcv genotype 1–4, advanced liver fibrosis) and, most of all, side effects profile resulting in poor tolerability and treatment contraindication in some patient subsets (decompensated liver disease and autoimmune disorders).2 the recent availability of culture cell models provided deeper insight in understanding hcv life cycle and was the basis for the development of new drugs targeting non-structural hcv proteins involved in viral replication process, such as ns3 and ns5a/b (figure 1 and table 1). |
| PubMedID- 24925642 | The aim of the present study was to measure the influence of chronic infection with viral hepatitis c (chc) genotype 1 and 4 on serum levels of activin-a, activin-b and follistatin, and to determine their correlations with viral load, liver damage, interleukin-6 (il-6) and tumour necrosis factor (tnf)-alpha. |
| PubMedID- 23613990 | chronic infection with hepatitis c virus (hcv) leads to exhaustion and death of hcv-specific t-cells (reviewed in ) but may also cause defects in overall immune function. |